Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ: ANIP) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 27.6% year on year to $290.8 million. The company expects the full year’s revenue to be around $1.11 billion, close to analysts’ consensus estimates. Its non-GAAP profit of $2.70 per share was 23.8% above analysts’ consensus estimates.
For more on ANI Pharmaceuticals, read our free full research report.
ANI Pharmaceuticals (ANIP) Q3 2026 highlights:
- Revenue $290.8 million vs S&P analysts’ consensus estimates of $278.7 million (27.6% year-on-year growth, 4.3% beat)
- Adjusted EPS $2.70 vs S&P analysts’ consensus estimates of $2.18 (23.8% beat)
- Adjusted EBITDA $83.3 million vs analysts’ consensus estimates of $69.44 million (28.6% margin, 20% beat)
- Revenue guidance The company reconfirmed its revenue guidance for the full year of $1.11 billion at the midpoint
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $9.54 at the midpoint, a 1.1% increase
- EBITDA guidance $295 million at the midpoint for the full year, above analysts’ consensus estimates of $291.2 million
- Operating margin 18%, up from 15.9% in the same quarter last year
- Market capitalization $1.54 billion
“In the third quarter, ANI delivered strong financial results, while advancing our transformation into a leading Rare Disease company,” said Nikhil Lalwani, President and CEO of ANI. “Cortrophin Gel delivered solid growth, driven by momentum from the gout expansion and continued progress in our existing specialties, while our Generics business continued to outperform. We also executed on our capital allocation strategy by repurchasing shares and expanding the scope and scale of our Rare Disease business through our offer to acquire Egetis Therapeutics. This acquisition would add an FDA-approved rare disease therapy with significant long-term growth potential, that is poised to address the unmet need of patients with MCT8 deficiency who have no other approved treatment options.”
Revenue growth
A company’s long-term performance is an indicator of its overall quality. Even a bad business can perform well for one or two quarters, but a top-tier one grows for years. ANI Pharmaceuticals’s 37.4% annualized revenue growth over the last five years was strong. Its growth beat the average healthcare company and shows its offerings resonate with customers.
Long-term growth matters most, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. ANI Pharmaceuticals’s annualized revenue growth of 36.9% over the last two years aligns with its five-year trend, suggesting its demand was predictably strong. 
This quarter, ANI Pharmaceuticals reported strong year-on-year revenue growth of 27.6%, and its $290.8 million of revenue topped Wall Street’s consensus estimates by 4.3%.
Looking ahead, sell-side analysts expect revenue to grow 15.2% over the next 12 months, according to S&P, a deceleration versus the last two years. Still, this projection is strong and implies the market is forecasting success for its products and services.
Adjusted operating margin
Adjusted operating margin is one of the best measures of profitability because it shows how much a company earns after subtracting all core expenses, such as marketing and research and development. It also removes various one-time costs to give a clearer picture of normalized profits.
ANI Pharmaceuticals has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, with an average adjusted operating margin of 24.8%.
Looking at the trend in its profitability, ANI Pharmaceuticals’s adjusted operating margin rose by 11.1 percentage points over the last five years, as its revenue growth gave it operating leverage.
This quarter, ANI Pharmaceuticals generated an adjusted operating margin of 22%, down 4.2 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.
Earnings per share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share, or EPS, points to the profitability of that growth – for example, a company could inflate its revenue through excessive spending on advertising and promotions.
ANI Pharmaceuticals’s EPS grew at a strong 21.4% compounded annual growth rate over the last five years. Despite its adjusted operating margin improvement during that time, this performance was lower than its 37.4% annualized revenue growth, indicating that non-fundamental factors such as interest and taxes affected its ultimate earnings.
A closer look at ANI Pharmaceuticals’s earnings helps explain the drivers of its performance. A five-year view shows ANI Pharmaceuticals has diluted its shareholders, growing its share count by 79%. This dilution overshadowed its increased operational efficiency and has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don’t tell us as much about a company’s fundamentals. 
In Q3, ANI Pharmaceuticals reported adjusted EPS of $2.70, up from $2.04 in the same quarter last year. This result easily cleared analysts’ consensus estimates, a positive outcome for shareholders. Over the next 12 months, Wall Street expects ANI Pharmaceuticals’s full-year EPS to grow 4% from $9.29 to $9.66, according to S&P.
Key takeaways from ANI Pharmaceuticals’s Q3 results
ANI Pharmaceuticals delivered a solid quarter, topping analysts’ consensus estimates for both EPS and revenue. Shares edged higher 1.9% to $73.01 immediately after the results.
ANI Pharmaceuticals had a solid quarter, but one earnings result doesn’t necessarily make the stock a buy. That decision requires considering its valuation, business quality and latest quarterly results. For more on ANI Pharmaceuticals, read the full research report here (it’s free).
